相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma
Peter Moosmann et al.
LEUKEMIA & LYMPHOMA (2010)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Acyclovir to Prevent Reactivation of Varicella Zoster Virus (Herpes Zoster) in Multiple Myeloma Patients Receiving Bortezomib Therapy
Eric Vickrey et al.
CANCER (2009)
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
Sven de Vos et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The emerging role of bendamustine in follicular lymphoma
Jonathan W. Friedberg
LEUKEMIA & LYMPHOMA (2009)
Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib
Ludek Pour et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
Issa F. Khouri et al.
BLOOD (2008)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
K. Sue Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
SJ Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
New treatment options have changed the survival of patients with follicular lymphoma
RI Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Improved survival of follicular lymphoma patients in the United States
WT Swenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial
HC Schouten et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
